OMCL
NEUTRAL
$37.53
Live
Omnicell, Inc. · NASDAQ
Target $57.43
(+53.0%)
$22.66
52W Range
$55.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$1.71B
P/E
938.25
ROE
0.2%
Profit margin
0.2%
Debt/Equity
0.17
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
OMCL presents a stark contrast between strong financial health and poor valuation metrics. While the Piotroski F-Score of 7/9 indicates a strong operational baseline and the balance sheet is lean with a Debt/Equity ratio of 0.17, the stock trades at a massive premium to its Graham Number ($4.96) and Intrinsic Value ($0.28). The astronomical trailing P/E of 938.25 is offset by a reasonable Forward P/E of 17.98, suggesting the market is pricing in a significant earnings recovery. However, razor-thin profit margins (0.17%) and bearish insider activity temper the strong analyst 'Strong Buy' consensus.
Key Strengths
Strong Piotroski F-Score (7/9) indicating operational health
Very low leverage with a Debt/Equity ratio of 0.17
Strong analyst consensus with a target price of $57.43
Consistent track record of beating earnings estimates over 25 quarters
Healthy liquidity with a Current Ratio of 1.43
Key Risks
Extreme trailing P/E ratio (938.25) indicating severe overvaluation based on current earnings
Negligible profit margins (0.17%) leaving no room for operational error
Bearish insider sentiment with 7 sell transactions and 0 buys
Sluggish year-over-year revenue growth of only 2.30%
Significant long-term price erosion (5Y Change: -72.8%)
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
-66.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
15
55
30
85
0
AI Verdict
Speculative Recovery
Key drivers: Balance sheet strength, Forward earnings expectations, Valuation disconnect
Confidence
85%
Value
15/100
Stock trades at a massive premium to defensive fair value, relying entirely on forward-looking growth.
Positives
- Reasonable Price/Book (1.37)
Watchpoints
- Trailing P/E of 938.25
- Price far exceeds Graham Number ($4.96)
Future
55/100
Future outlook depends on the transition from thin margins to the projected earnings growth.
Positives
- Forward P/E of 17.98 suggests earnings normalization
- Strong analyst target price
Watchpoints
- Low current revenue growth (2.3%)
- Negative recent Q/Q EPS growth (-21.6%)
Past
30/100
Historical performance has been poor, though short-term momentum is turning positive.
Positives
- Recent 6-month price recovery (+25.4%)
Watchpoints
- Devastating 5-year return (-72.8%)
- Consistent long-term downtrend
Health
85/100
Financial solvency is the company's strongest attribute.
Positives
- Piotroski F-Score of 7/9
- Low Debt/Equity (0.17)
- Current Ratio > 1.0
Watchpoints
- Quick Ratio slightly below 1.0 (0.90)
Dividend
0/100
Non-dividend paying growth/recovery stock.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$37.53
Analyst Target
$57.43
Upside/Downside
+53.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OMCL and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
Primary
|
-72.8% | -36.3% | +19.7% | +25.4% | +9.4% | +5.5% |
|
NRIX
Nurix Therapeutics, Inc.
Peer
|
-47.4% | +33.4% | +65.5% | +77.6% | +6.0% | -0.3% |
|
HRMY
Harmony Biosciences Holdings, Inc.
Peer
|
+0.6% | -8.8% | -0.3% | +8.8% | +0.3% | +4.2% |
|
NTLA
Intellia Therapeutics, Inc.
Peer
|
-78.8% | -61.9% | +103.0% | -42.4% | +11.7% | +7.7% |
|
INVA
Innoviva, Inc.
Peer
|
+103.6% | +101.2% | +39.0% | +37.0% | +6.0% | +3.4% |
OMC
Omnicell, Inc.
Primary
5Y
-72.8%
3Y
-36.3%
1Y
+19.7%
6M
+25.4%
1M
+9.4%
1W
+5.5%
NRI
Nurix Therapeutics, Inc.
Peer
5Y
-47.4%
3Y
+33.4%
1Y
+65.5%
6M
+77.6%
1M
+6.0%
1W
-0.3%
HRM
Harmony Biosciences Holdings, Inc.
Peer
5Y
+0.6%
3Y
-8.8%
1Y
-0.3%
6M
+8.8%
1M
+0.3%
1W
+4.2%
NTL
Intellia Therapeutics, Inc.
Peer
5Y
-78.8%
3Y
-61.9%
1Y
+103.0%
6M
-42.4%
1M
+11.7%
1W
+7.7%
INV
Innoviva, Inc.
Peer
5Y
+103.6%
3Y
+101.2%
1Y
+39.0%
6M
+37.0%
1M
+6.0%
1W
+3.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
938.25
Forward P/E
17.98
PEG Ratio
N/A
P/B Ratio
1.37
P/S Ratio
1.44
EV/Revenue
1.45
EV/EBITDA
37.6
Market Cap
$1.71B
Profitability
Profit margins and return metrics
Profit Margin
0.17%
Operating Margin
2.2%
Gross Margin
42.88%
ROE
0.17%
ROA
0.36%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.3%
Earnings Growth
N/A
Q/Q Revenue Growth
+2.32%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.17
Low debt
Current Ratio
1.43
Good
Quick Ratio
0.9
Poor
Cash/Share
$4.33
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
41.5%
Op. Margin
0.1%
Net Margin
-0.6%
Total Assets
$2.0B
Liabilities
$0.7B
Equity
$1.2B
Debt/Equity
0.60x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
60%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-28
$N/A
2026-02-05
$0.4
-19.4% surprise
2025-10-30
$0.51
+40.7% surprise
2025-07-31
$0.45
+66.7% surprise
Healthcare Sector Comparison
Comparing OMCL against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
P/E Ratio
938.25
This Stock
vs
89.02
Sector Avg
+954.0%
(Expensive)
Return on Equity (ROE)
0.17%
This Stock
vs
-100.15%
Sector Avg
-100.2%
(Below Avg)
Profit Margin
0.17%
This Stock
vs
-13.63%
Sector Avg
-101.3%
(Weaker)
Debt to Equity
0.17
This Stock
vs
3.22
Sector Avg
-94.8%
(Less Debt)
Revenue Growth
2.3%
This Stock
vs
121.05%
Sector Avg
-98.1%
(Slower)
Current Ratio
1.43
This Stock
vs
4.55
Sector Avg
-68.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
|
NEUTRAL | $1.71B | 938.25 | 0.2% | 0.2% | $37.53 | |
|
NRIX
Nurix Therapeutics, Inc.
|
NEUTRAL | $1.69B | - | -61.4% | -% | $16.3 | Compare |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
NEUTRAL | $1.67B | 10.74 | 20.8% | 18.3% | $28.89 | Compare |
|
NTLA
Intellia Therapeutics, Inc.
|
BEARISH | $1.76B | - | -53.5% | -% | $14.94 | Compare |
|
INVA
Innoviva, Inc.
|
BULLISH | $1.77B | 7.2 | 29.1% | 65.9% | $23.76 | Compare |
OMCL
Omnicell, Inc.
NEUTRAL
Mkt Cap
$1.7B
P/E
938.2
ROE
0.2%
Price
$37.53
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | MANLEY COREY J | Officer | Stock Award | 25,132 | - |
| 2026-04-01 | NJOKU NNAMDI | Chief Operating Officer | Stock Award | 46,296 | - |
| 2026-04-01 | RADFORD HARLAN BAIRD III | Chief Financial Officer | Stock Award | 37,037 | - |
| 2026-04-01 | NUTT BRIAN H | Officer | Stock Award | 5,556 | - |
| 2026-04-01 | LIPPS RANDALL A | Chief Executive Officer | Stock Award | 90,939 | - |
| 2026-03-16 | MANLEY COREY J | Officer | Sale | 7,405 | $256,879 |
| 2026-03-13 | LIPPS RANDALL A | Chief Executive Officer | Stock Award | 79,494 | - |
| 2026-03-13 | MANLEY COREY J | Officer | Stock Award | 22,445 | - |
| 2026-03-13 | NJOKU NNAMDI | Chief Operating Officer | Stock Award | 37,409 | - |
| 2026-02-17 | MANLEY COREY J | Officer | Sale | 4,243 | $155,251 |
| 2026-01-08 | MANLEY COREY J | Officer | Sale | 6,106 | $304,689 |
| 2025-12-16 | MANLEY COREY J | Officer | Sale | 278 | $12,037 |
| 2025-12-03 | MANLEY COREY J | Officer | Sale | 6,106 | $243,629 |
| 2025-12-01 | LIPPS RANDALL A | Chief Executive Officer | Sale | 28,250 | $1,016,093 |
| 2025-12-01 | LIPPS RANDALL A | Chief Executive Officer | Option Exercise | 28,250 | $782,525 |
MANLEY COREY J
Officer
2026-04-01
25,132 shares
NJOKU NNAMDI
Chief Operating Officer
2026-04-01
46,296 shares
RADFORD HARLAN BAIRD III
Chief Financial Officer
2026-04-01
37,037 shares
NUTT BRIAN H
Officer
2026-04-01
5,556 shares
LIPPS RANDALL A
Chief Executive Officer
2026-04-01
90,939 shares
MANLEY COREY J
Officer
2026-03-16
7,405 shares
·
$256,879
LIPPS RANDALL A
Chief Executive Officer
2026-03-13
79,494 shares
MANLEY COREY J
Officer
2026-03-13
22,445 shares
NJOKU NNAMDI
Chief Operating Officer
2026-03-13
37,409 shares
MANLEY COREY J
Officer
2026-02-17
4,243 shares
·
$155,251
MANLEY COREY J
Officer
2026-01-08
6,106 shares
·
$304,689
MANLEY COREY J
Officer
2025-12-16
278 shares
·
$12,037
MANLEY COREY J
Officer
2025-12-03
6,106 shares
·
$243,629
LIPPS RANDALL A
Chief Executive Officer
2025-12-01
28,250 shares
·
$1,016,093
LIPPS RANDALL A
Chief Executive Officer
2025-12-01
28,250 shares
·
$782,525
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
Piper Sandler
2026-02-06
Overweight
Overweight
Benchmark
2026-02-02
Buy
Buy
Keybanc
2026-01-08
Sector Weight
Overweight
Wells Fargo
2026-01-05
Overweight
Overweight
B of A Securities
2025-12-09
Neutral
Neutral
Benchmark
2025-12-09
Buy
Buy
Benchmark
2025-10-31
Buy
Buy
Past News Coverage
Recent headlines mentioning OMCL from our newsroom.
Newest → oldest
No matching news yet.